Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952698 | 0.88 | POLB (0.42) | POLBNPSR1HTR2CPDE5AGFER | |
| SCHEMBL12944880 | 0.88 | TGM2 (0.41) | CTSKPOLBCTSBCTSSTGM2 | |
| SCHEMBL29993724 | 0.88 | TGM2 (0.41) | CTSKPOLBCTSBCTSSTGM2 | |
| SCHEMBL946384 | 0.88 | TGM2 (0.41) | CTSKPOLBCTSBCTSSTGM2 | |
| SCHEMBL5019943 | 0.88 | TGM2 (0.41) | CTSKPOLBCTSBCTSSTGM2 | |
| SCHEMBL5019960 | 0.83 | TGM2 (0.40) | CTSKPOLBCTSBCTSSTGM2 | |
| SCHEMBL950380 | 0.83 | BIRC3 (0.44) | CTSKPOLBCTSBCTSSNPSR1 | |
| SCHEMBL21286695 | 0.83 | BIRC3 (0.44) | CTSKPOLBCTSBCTSSNPSR1 | |
| SCHEMBL5019944 | 0.83 | BIRC3 (0.44) | CTSKPOLBCTSBCTSSNPSR1 | |
| SCHEMBL12944881 | 0.83 | BIRC3 (0.44) | CTSKPOLBCTSBCTSSNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951147-B2 | SMAC mimetic | MEDIVIR AB (SE) | 2024-04-09 | — | — | US | disclosed |
| US-20200282002-A1 | SMAC Mimetic | MEDIVIR AB (SE) | 2020-09-10 | — | — | US | disclosed |
| US-10596220-B2 | SMAC mimetic | MEDIVIR AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190255139-A1 | SMAC Mimetic | MEDIVIR AB (SE) | 2019-08-22 | — | — | US | disclosed |
| US-10314881-B2 | SMAC mimetic | MEDIVIR AB (SE) | 2019-06-11 | — | — | US | disclosed |
| US-20180303897-A1 | SMAC Mimetic | MEDIVIR AB (SE) | 2018-10-25 | — | — | US | disclosed |
| US-10034912-B2 | SMAC Mimetic | TetraLogic Birinapant UK Ltd. (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170182116-A1 | SMAC Mimetic | MEDIVIR AB (SE) | 2017-06-29 | — | — | US | disclosed |
| US-20150158908-A1 | SMAC Mimetic for Treating Myelodysplastic Syndromes | TETRALOGIC BIRINAPANT UK LTD (GB) | 2015-06-11 | — | — | US | disclosed |
| US-8986993-B2 | SMAC mimetic for treating myelodysplastic syndromes | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140073579-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8603816-B2 | SMAC mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130012564-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8283372-B2 | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120115922-A1 | SMAC MIMETEC | MEDIVIR AB (SE) | 2012-05-10 | — | — | US | disclosed |
| US-20110003877-A1 | SMAC Mimetic | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012564-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-10596220-B2 | SMAC mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2382/4885 |
| US-20150158908-A1 | SMAC Mimetic for Treating Myelodysplastic Syndromes | MCL1, MPL, THPO | CTSK 3669/4885POLB 356/4885CTSB 2982/4885 |
| US-20110003877-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-10314881-B2 | SMAC mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-20170182116-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2382/4885 |
| US-11951147-B2 | SMAC mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2382/4885 |
| US-10034912-B2 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-20120115922-A1 | SMAC MIMETEC | SMARCC1, SMARCC2, SMARCE1 | CTSK 3082/4885POLB 83/4885CTSB 2612/4885 |
| US-20140073579-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-20200282002-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2382/4885 |
| US-20190255139-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
| US-20180303897-A1 | SMAC Mimetic | SMARCC1, SMARCC2, MCL1 | CTSK 3104/4885POLB 126/4885CTSB 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.